ACE and cancer: Population studies investigating the association of RAS inhibitor (RASi) use, ARBs, and ACE inhibitors (ACEis), with cancer incidence or survival have yielded mixed, yet mostly positive results (Table 2) [10, 12, 13, 15–41].